QurAlis has partnered with Eli Lilly to develop and commercialize QurAlis' QRL-204, a splice-switching antisense oligonucleotide (ASO) designed to fix UNC13A function, focused on treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
According to the agreement, Eli Lilly will be granted global rights to develop and commercialize QRL-204 and other UNC13A-targeting compounds, for which QurAlis will receive an initial payment of USD 45 million along with possible future payments up to USD 577 million and royalties on net sales and equity investment. The agreement also includes a collaborative R&D program to identify and develop additional candidates targeting UNC13A, using QurAlis' proprietary FlexASO Splice Modulator Platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.